EU Rejects Lilly’s Alzheimer’s Drug Kisunla, Following Same Path as Rival Leqembi

The European Union’s CHMP said that the benefits of the drug, already approved in the U.S., do not outweigh the risk of potentially fatal brain swelling and bleeding.